Addition of Etoricoxib During Concurrent Chemo-radiation of Cervical Cancer Patients Could Result in Faster Resolution of Gross Disease: A Prospective Single-Institution Study
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):1–31.
Dutta S, Biswas N, Muhkherjee G. Evaluation of socio-demographic factors for non-compliance to treatment in locally advanced cases of cancer cervix in a rural medical college hospital in India. Indian J Palliat Care. 2013;19(3):158–65.
Doll CM, Winter K, Gaffney DK, et al. COX-2 expression and survival in patients with locally advanced treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128. Int J Gynecol Cancer. 2013;23(1):176–83.
Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358:781–6.
Jung YW, Lee SH, Paek JH, et al. Acute toxicity of cyclooxygenase-2 inhibitor rofecoxib as a radiosensitizer for concurrent chemoradiation in the treatment of uterine cervical cancer. J Gynecol Oncol. 2009;20(3):151–7.
Laube M, Kniess T, Pietzsch J. Development of antioxidant COX-2 inhibitors as radioprotective agents for radiation therapy—a hypothesis-driven review. Antioxidants (Basel). 2016;5(2):14.
Saha D, Choy H. Potential for combined modality therapy of cyclooxygenase inhibitors and radiation. Prog Exp Tumor Res. 2003;37:193–209.
Na YR, Yoon YN, Son DI, Seok SH. Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. PLoS ONE. 2013;8(5):e63451.
Peng JP, Su CY, Chang HC, Chai CY, Hung WC. Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx. Hum Pathol. 2002;33(1):100–4.
Byatnal AA, Byatnal A, Sen S, Guddattu V, Solomon MC. Cyclooxygenase-2—an imperative prognostic biomarker in oral squamous cell carcinoma—an immunohistochemical study. Pathol Oncol Res. 2015;21(4):1123–31.
Kuo KT, Chow KC, Wu YC, Lin CS, Wang HW, Li WY, Wang LS. Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma. Ann Thorac Surg. 2003;76(3):909–14.
Jawanjal P, Salhan S, Dhawan I, Das N, Aggarwal R, Tripathi R, Rath G. Augmented activity of cyclooxygenase-2 in tissue and serum of patients with cervical cancer. J Clin Lab Anal. 2016;30(6):1198–207.
Chen YJ, Wang LS, Wang PH, Lai CR, Yen MS, Ng HT, Yuan CC. High cyclooxygenase-2 expression in cervical adenocarcinomas. Gynecol Oncol. 2003;88(3):379–85.
Munkarah A, Ali-Fehmi R. COX-2: a protein with an active role in gynecological cancers. Gynecol Oncol. 2008;109(1):140–5.
Kim HJ, Wu HG, Park IA, Ha SW. High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;55(1):16–20.
Kim YB, Kim GE, Cho NH, Pyo HR, Shim SJ, Chang SK, Park HC, Suh CO, Park TK, Kim BS. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer. 2002;95(3):531–9.
Chen HH, Su WC, Chou CY, Guo HR, Ho SY, Que J, Lee WY. Increased expression of nitric oxide synthase and cyclooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63(4):1093–100.
Choy H, Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst. 2003;95(19):1440–52.
Escudero-Condreas A, Cervantes JVM, Collantes-Estevez E. Update on the clinical Pharmacology of Etoricoxib, a potent cyclooxygenase-2 inhibitor. Future Rheumatol. 2007;2(6):545–65.
Herrera FG, Chan P, Doll C, Milosevic M, Oza A, Syed A, Pintilie M, Levin W, Manchul L, Fyles A. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat Oncol Biol Phys. 2007;67(1):97–103.
Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M, Williams CJ. A systematic review of acute and late toxicity of concomitant chemo-radiation for cervical cancer. Radiother Oncol. 2003;68:217–26.
Jeyaseelan V, Pavamani SP, Ram TS, Thomas EM, Varghese SS, Viswanathan PN. Concurrent chemo-irradiation with weekly cisplatin and paclitaxel in the treatment of locally advanced squamous cell carcinoma of cervix: a phase II study. J Cancer Res Ther. 2014;10(2):330–6.
Saibishkumar EP, Patel FD, Sharma SC. Results of a phase II trial of concurrent chemo-radiation in the treatment of locally advanced carcinoma of uterine cervix: an experience from India. Bull Cancer. 2005;92(1):E7–12.